There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.

While drug prices and insurance companies often draw scrutiny, the report shifts the spotlight to hospitals—particularly nonprofit systems—as the main contributor to inflating costs.

The 21st Century Cures Act expanded enrollment eligibility for Medicare Advantage to include people with end-stage kidney disease. Sometimes aggressive marketing followed.

Most gene therapies being studied for eye diseases are in earlier phases of development, and a third of the gene therapies being investigated are for age-related macular degeneration.

Ways health systems can support care teams treating postpartum hemorrhage and the potential impacts of the Trump administration’s diversity, equity and inclusion (DEI) policies, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at the University of Illinois.

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.

Here’s what you missed this week on Managed Healthcare Executive.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host disease prophylaxis.

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.

The findings were consistent with those seen in a study of Western study participants.

In a report by JPMorgan Chase's Morgan Health, it was found that 37% of women with employer-sponsored insurance said meeting their deductibles is difficult, and 36% reported that their plans didn’t cover care they expected—or paid less than anticipated.

This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.

Researchers at Yale School of Medicine have determined that a panel of biomarkers can help physicians better understand kidney disease in children.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung cancer biomarker subtypes.

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

A new report by Commonwealth Fund ranks all 50 states and the District of Columbia across 50 indicators covering access, quality, outcomes and equity from data collected up to 2023.

Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.

Headspace has debuted a virtual therapy service called Therapy by Headspace that blends licensed care with AI support and insurance access to improve affordability and reach, according to a news release.

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new data from an additional FDA-requested trial.

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.